No cookies!

Cookies disabled. It’s not us, it’s your browser. Your Web browser must have cookies enabled for you to use all of the site’s functions.

TOLERABIILITY

Xiidra offers a proven tolerability profile1

In 5 clinical studies of Dry Eye Disease with lifitegrast ophthalmic solution, 1401 patients received at least one dose of lifitegrast (1287 of which received Xiidra). The majority of patients (84%) had up to 3 months of treatment exposure. 170 patients were exposed to Xiidra for approximately 12 months.1

Across 5 clinical studies, the most common adverse reactions (5-25%) were instillation site irritation, dysgeusia, and reduced visual acuity1

In the 12-month, multicenter, randomized, double-masked, phase 3 study, the safety of Xiidra compared to vehicle was evaluated in a total of 331 adults with Dry Eye Disease.1,2

CLICK TO ENLARGE

Incidence and severity of most frequent adverse events (>5%) in a 12-month safety study2*

The majority of ocular adverse reactions were considered mild to moderate in the 12-month study.2

Percentage value indicates the proportion of participants who experienced each type of adverse event.
Values inside bars = number of participants
*Adverse events occurring in >5% of participants in either treatment group.

Want to learn more about Xiidra and Shire?

Tell us your e-mail address:

*First Name *Last Name
*CHOOSE AN OPTION

*All fields are required.

For US residents only.
All personal and/or medical information you have provided will be kept confidential and will not be used or distributed to anyone for any purpose other than what is explained in our privacy notice statement. We encourage you to read our privacy notice statement by clicking on this link: Review Shire privacy notice statement.

This consent will be in effect until such time as you opt out of the program.

CANCEL
NIICE Thanks for registering. We’re really looking forward to sending you updates.

Incidence and severity of most frequent adverse events (>5%) in a 12-month safety study2*

Percentage value indicates the proportion of participants who experienced each type of adverse event.
Values inside bars = number of participants
*Adverse events occurring in >5% of participants in either treatment group.

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Please click here for Full Prescribing Information.

References

  1. Xiidra [Prescribing Information]. Lexington, MA: Shire US.
  2. Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741-748.